Inflammatory CADASIL: the cross-link between CADASIL and multiple sclerosis: a report of two cases and systematic review of the literature

• by Ali Mahmoud Ahmed, Niraj Mistry, Ahmed Samir Gehad, Abdelmonem M. Hassan

• June 5, 2026

HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling

• by Elsa M. Reyes-Reyes, Dhanalakshmi Chinnasamy, Michael D. Trial, Fernando Fernandez, Vincent D. Nguyen, Qianying He, Angel-Grace Leslie, Jessica Begay, Jessica Triplett, David Bradford, Carolina Figueroa, Jean P. Wiegand, Kathleen E. Rodgers

• June 16, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

• by Kathryn Wighton

• June 15, 2026

• 3 min

Case Report: Multiple sclerosis and Neurofibromatosis type 1: a rare comorbidity

• by Angela Musci, Luigi Bonan, Eleonora Manzoni, Michele Carbonelli, Giulia Amore, Rocco Liguori, Valerio Carelli, Francesco Ventruto, Alessandra Lugaresi, Chiara La Morgia

• July 9, 2026